223 related articles for article (PubMed ID: 26952512)
1. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
Voboril R; Rychterova V; Voborilova J; Kubecova M; Fanta J; Dvorak J
Neoplasma; 2016; 63(3):462-70. PubMed ID: 26952512
[TBL] [Abstract][Full Text] [Related]
2. Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data.
Voboril R; Voborilova J; Rychterova V; Jirasek T; Dvorak J
Clin Exp Metastasis; 2008; 25(4):491-6. PubMed ID: 18324356
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-κB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy.
Berardi R; Maccaroni E; Mandolesi A; Mantello G; Onofri A; Biscotti T; Pierantoni C; Siquini W; Marmorale C; Guerrieri M; Bearzi I; Cascinu S
Dig Liver Dis; 2012 Jul; 44(7):617-22. PubMed ID: 22440241
[TBL] [Abstract][Full Text] [Related]
4. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients.
Montagut C; Tusquets I; Ferrer B; Corominas JM; Bellosillo B; Campas C; Suarez M; Fabregat X; Campo E; Gascon P; Serrano S; Fernandez PL; Rovira A; Albanell J
Endocr Relat Cancer; 2006 Jun; 13(2):607-16. PubMed ID: 16728586
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma.
Long YM; Ye S; Rong J; Xie WR
World J Gastroenterol; 2008 Aug; 14(30):4739-44. PubMed ID: 18720533
[TBL] [Abstract][Full Text] [Related]
6. Strong cytoplasmic expression of NF-κB/p65 correlates with a good prognosis in patients with triple-negative breast cancer.
Baba M; Takahashi M; Yamashiro K; Yokoo H; Fukai M; Sato M; Hosoda M; Kamiyama T; Taketomi A; Yamashita H
Surg Today; 2016 Jul; 46(7):843-51. PubMed ID: 26494004
[TBL] [Abstract][Full Text] [Related]
7. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Bosset JF; Calais G; Mineur L; Maingon P; Stojanovic-Rundic S; Bensadoun RJ; Bardet E; Beny A; Ollier JC; Bolla M; Marchal D; Van Laethem JL; Klein V; Giralt J; Clavère P; Glanzmann C; Cellier P; Collette L;
Lancet Oncol; 2014 Feb; 15(2):184-90. PubMed ID: 24440473
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of β-arrestin1 and NF-кB is associated with cancer progression and poor prognosis in lung adenocarcinoma.
Yu J; Wang L; Zhang T; Shen H; Dong W; Ni Y; Du J
Tumour Biol; 2015 Aug; 36(8):6551-8. PubMed ID: 25820700
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy.
O'Neil BH; Funkhouser WK; Calvo BF; Meyers MO; Kim HJ; Goldberg RM; Bernard SA; Caskey L; Deal AM; Wright F; Baldwin AS; Tepper JE
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):705-11. PubMed ID: 20630669
[TBL] [Abstract][Full Text] [Related]
10. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
11. Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Liersch T; Langer C; Ghadimi BM; Kulle B; Aust DE; Baretton GB; Schwabe W; Häusler P; Becker H; Jakob C
J Clin Oncol; 2006 Sep; 24(25):4062-8. PubMed ID: 16943523
[TBL] [Abstract][Full Text] [Related]
12. Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Avallone A; Pecori B; Bianco F; Aloj L; Tatangelo F; Romano C; Granata V; Marone P; Leone A; Botti G; Petrillo A; Caracò C; Iaffaioli VR; Muto P; Romano G; Comella P; Budillon A; Delrio P
Oncotarget; 2015 Oct; 6(30):30394-407. PubMed ID: 26320185
[TBL] [Abstract][Full Text] [Related]
13. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma.
Izzo JG; Malhotra U; Wu TT; Ensor J; Luthra R; Lee JH; Swisher SG; Liao Z; Chao KS; Hittelman WN; Aggarwal BB; Ajani JA
J Clin Oncol; 2006 Feb; 24(5):748-54. PubMed ID: 16401681
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of nuclear factor κ B expression in patients with advanced cervical cancer undergoing radiation therapy followed by hysterectomy.
Baiocchi G; Begnami MD; Fukazawa EM; Oliveira RA; Faloppa CC; Kumagai LY; Badiglian-Filho L; Pellizzon AC; Maia MA; Jacinto AA; Soares FA; Lopes A
J Clin Pathol; 2012 Jul; 65(7):614-8. PubMed ID: 22447917
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F; Bengala C; Losi L; Pagano M; Iachetta F; Dealis C; Jovic G; Depenni R; Zironi S; Falchi AM; Luppi G; Conte PF
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1455-61. PubMed ID: 17445998
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Cao WG; Zhao R; Xi WQ; Ma T; Li H; Xu HP; Che JF; Jin YN
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):225-7. PubMed ID: 17649643
[TBL] [Abstract][Full Text] [Related]
18. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Tseng MSF; Zheng H; Ng IWS; Leong YH; Leong CN; Yong WP; Cheong WK; Tey JCS
Singapore Med J; 2018 Jun; 59(6):305-310. PubMed ID: 29167909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
